Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic

Internal Medicine Journal

Volumn 33, Issue 11, 2003, Pages 500-504

  Kontorinis, N ^a   Garas, G ^a   Young, J ^a   Speers, D ^a   Chester, B P ^a   MacQuillan, G C ^a   De Boer, B ^a   Chapman, M D ^a   Forster, E ^a   Jeffrey, G P ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Hepatitis C virus; Interferon ; Ribavirin; Shared care

Indexed keywords

ALPHA2B INTERFERON; INTERFERON; RIBAVIRIN;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; COMBINATION CHEMOTHERAPY; COMMUNITY CARE; DEPRESSION; DIARRHEA; DRUG RESPONSE; DRUG TOLERABILITY; ECZEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL CARE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INSOMNIA; LETHARGY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MENTAL HEALTH CARE; MYALGIA; NAUSEA; NEUTROPENIA; NURSING; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSORIASIS; RASH; RIGOR; SHARED CARE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS TYPING; VOMITING;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RIBAVIRIN; RNA, VIRAL;

EID: 10744225748     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-5994.2003.00410.x     Document Type: Article

References (21)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences temporal trends. Seminars Liver Dis 2000; 20: 1-16.
2. Farrell GC, Weltman M, Dingley J, Lin R. Epidemiology of hepatitis C virus infection in Australia. Gastroenterol Jpn 1993; 28: 32-6.
3. Alter JH, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection, a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35.
4. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. Interferon Alfa-2b alone or in combination with ribavirin as initial therapy for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
5. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-9.
6. Brind AM, Jeffrey GP, Harnet G, Reed WD. Interferon alfa 2B for chronic hepatitis C: analysis and outcome in 345 cases in a single Australian centre. J Gastroenterol Hepatol 1997; 12: A77.
7. Ostapowicz G, Bell SJ, Desmond PV. Severity of liver disease in hepatitis C infection contracted through injecting drug use. Aust NZ J Med 1999; 29: 776-81.
8. Freeman AJ, Zekry A, Whybin LR, Harvey CE, van Beek IA, de Kantzow SL et al. Hepatitis C prevalence among Australian injection drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s. Med J Aust 2000; 172: 588-91.
9. Chutaputti A. Adverse effects and other safety aspects of the hepatitis C antivirals. J Gastroenterol Hepatol 2000; 15: E156-E163.
10. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonk C et al. Treatment of hepatitis C virus-related cirrhosis: a randomised, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999; 29: 1870-5.
11. Shiratori Y, Yokosuka O, Nakata R, Ihori M, Hirota K, Katamoto T et al. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Hepatology 1999; 29: 1573-80.
12. Heathcote EJ, Schiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1666-72.
13. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 48 weeks versus interferon alfa 2-b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
14. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P et al. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatol 1996; 24: 778-88.
15. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001; 21: 266-71.
16. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utoli R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HC genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
17. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-9.
18. Hwang SJ, Luo JC, Chu CW, Lai CR, Lu CL, Tsay SH et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol 2001; 16: 190-5.
19. Lam NP, DeGuzman LJ, Pitrak D, Layden TJ. Clinical and histological predictors of response to interferon-alpha in patients with chronic hepatitis C viral infection. Dig Dis Sci 1994; 39: 2660-4.
20. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E et al. Peginterferon alpha-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
21. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.